Table 3:
Factors impacting branch vessel patency—entire cohorta
| Patent Branch Vessel | Occluded Branch Vessel | Univariate P Value | Multivariate P Value | OR (95% CI) | |
|---|---|---|---|---|---|
| Mean patient age (yr) | 54.4 ± 12.2 | 59.3 ± 10.2 | .04 | .179 | 1.03 (0.99–1.07) |
| Male | 26 (13.8%) | 4 (13.8%) | .996 | ||
| Acutely ruptured target lesion | 7/188 (3.7%) | 1/29 (3%) | .942 | ||
| Mean max aneurysm sac size | 5.6 ± 3.8 | 4.2 ± 2.3 | .067 | .117 | 0.87 (0.73–1.04) |
| Mean aneurysm neck size | 3.4 ± 1.7 | 3.0 ± 1.2 | .139 | ||
| Mean procedural time (min) | 206 ± 66 | 214 ± 60 | .513 | ||
| Mean fluoroscopy time (min) | 64 ± 36 | 62 ± 27 | .764 | ||
| >1 PED deployed | 17/188 (9.0%) | 1/29 (3.4%) | .309 | ||
| % PED classic | 107/125 (86%) | 18/29 (62.1%) | .601 | ||
| Balloon angioplasty | 13/188 (7%) | 1/29 (7%) | .479 | ||
| Mean PED diameter (mm) | 4.0 ± 0.5 | 3.5 ± 0.5 | <0.001 | .001 | 0.16 (0.06–0.45) |
| Mean Δmax size of parent vessel and PED | 0.22 ± 0.19 | 0.26 ± 0.26 | .405 | ||
| Mean Δmin size of parent vessel and PED | 0.77 ± 0.41 | 0.67 ± 0.40 | .230 | ||
| Branch vessel incorporation into aneurysm sac | 52/188 (28%) | 9/29 (31%) | .707 | ||
| Mean periprocedural P2Y12 | 127 ± 68 | 122 ± 80 | .379 | ||
| Intraprocedural administration of abciximab | 17/188 (9.0%) | 3/29 (10.3%) | .821 | ||
| Presence of endothelial hyperplasia | 43/185 (23%) | 10/29 (34%) | .192 | ||
| Mean length of DSA follow-up (mo) | 18.3 ± 9.9 | 20.1 ± 8.8 | .351 | ||
| A1 ACA | 7/11 (63.6%) | 4/11 (36.3%) | .021 | .813 | 1.29 (0.16–10.56) |
| Anterior choroidal artery | 30/31 (96.8%) | 1/31 (3.2%) | .073 | .092 | 0.10 (0.01–1.46) |
| PcomA | 26/39 (66.6%) | 13/39 (33.3%) | <.001 | .205 | 3.26 (0.52–20.28) |
| Ophthalmic artery | 118/125 (94%) | 8/125 (6%) | <.001 | 0.449 | 0.49 (0.08–3.07) |
Note:—ACA indicates anterior cerebral artery; max, maximum; min, minimum; PcomA, posterior communicating artery.
a
Percentages reflect analysis per branch vessel.